Hercules Capital, Inc. (HTGC) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Hercules Capital, Inc., a business development company (BDC) and regulated investment company (RIC), for the period ended June 30, 2026. The Company focuses on providing senior secured loans to high-growth, venture-backed technology and life sciences companies. As of July 23, 2026, there were 187,164,000 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Investment Income | $149.1 million | $137.5 million | $290.7 million | $257.0 million |
| Net Investment Income | $92.9 million | $88.7 million | $181.0 million | $166.2 million |
| Net Realized Gain (Loss) | $7.7 million | ($57.6 million) | $7.1 million | ($59.2 million) |
| Net Change in Unrealized Appreciation (Depreciation) | $29.6 million | $47.8 million | ($15.4 million) | $22.2 million |
| Net Increase in Net Assets from Operations | $130.2 million | $78.9 million | $172.7 million | $129.2 million |
| Net Asset Value (NAV) per Share | $12.15 | $11.84 | $12.15 | $11.84 |
| Total Debt Outstanding | $2.36 billion | $2.05 billion | $2.36 billion | $2.05 billion |
| Cash and Cash Equivalents | $48.2 million | $57.0 million | $48.2 million | $57.0 million |
| Weighted Average Cost of Debt | 5.2% | 5.0% | 5.1% | 4.9% |
Material Changes vs. Prior Period
- Revenue Growth: Total investment income increased by 8.5% year-over-year for the quarter and 13.1% year-over-year for the six-month period, driven primarily by an increase in the weighted average principal outstanding.
- Realized Gains: The Company reported a net realized gain of $7.7 million for Q2 2026, a significant improvement from the $57.6 million net realized loss in Q2 2025. The 2026 gains were driven by sales of equity positions (e.g., Axsome Therapeutics) and acquisitions (Armis, Reltio), whereas 2025 losses were driven by write-offs (Khoros, Annex Cloud).
- Unrealized Performance: While Q2 2026 saw $29.6 million in unrealized appreciation, the six-month period ended with a net unrealized depreciation of $15.4 million, contrasting with $22.2 million in appreciation for the same period in 2025. This shift was attributed to widening credit spreads on debt investments offset by equity market recovery in the quarter.
- Expense Increases: Net operating expenses rose to $56.2 million for the quarter (from $48.7 million in 2025) due to higher interest costs on increased debt levels and higher variable compensation.
- Portfolio Composition: The portfolio fair value grew to $4.58 billion. The "Defense Technologies" sector saw significant growth, increasing from 3.1% to 5.5% of the portfolio, while "System Software" decreased from 10.6% to 8.2%.
Guidance, Outlook, and Risks
- Liquidity: As of June 30, 2026, the Company had approximately $652.9 million in available liquidity, including cash and borrowing capacity under credit facilities (SMBC and MUFG). The asset coverage ratio was 212.2% (excluding SBA debentures), well above the 150% regulatory minimum.
- Capital Markets: The Company issued $300 million in 5.35% unsecured notes due 2029 in February 2026. In July 2026 (subsequent event), the Company issued an additional $325 million in 6.30% notes due 2031.
- Distributions: The Board declared a quarterly distribution of $0.47 per share for Q2 2026 ($0.40 base + $0.07 supplemental). The Company maintains a dividend reinvestment plan.
- Risks:
- Concentration Risk: Six portfolio companies represented greater than 5% of net assets, including Marathon Health (8.1%) and Shield AI (6.8%).
- Interest Rate Risk: 97.8% of the debt portfolio is floating-rate with floors, providing some insulation against rate declines but exposing the Company to spread widening.
- Legal Proceedings: A putative shareholder class action lawsuit filed in March 2026 was voluntarily dismissed without prejudice in July 2026. Related derivative actions were stayed pending resolution.
Investor Verification Checklist
- Verify the sustainability of the $7.7 million realized gain in Q2 2026 compared to the significant write-offs in 2025.
- Monitor the "Defense Technologies" sector concentration, which grew to 5.5% of the portfolio, and the performance of top holdings like Shield AI.
- Review the impact of the $15.4 million net unrealized depreciation for the six-month period on future NAV.
- Confirm the Company's ability to maintain its 150% asset coverage ratio given the increase in total debt to $2.36 billion.
- Assess the status of the $408.2 million in unfunded commitments and the likelihood of drawdowns given current market conditions.